IDEAYA Biosciences, Inc. $IDYA Stock Holdings Raised by Candriam S.C.A.

Candriam S.C.A. grew its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 1.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,110,424 shares of the company’s stock after buying an additional 18,123 shares during the quarter. Candriam S.C.A. owned 1.26% of IDEAYA Biosciences worth $42,818,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. bought a new position in IDEAYA Biosciences in the 2nd quarter valued at approximately $331,452,000. Jupiter Topco LLC purchased a new stake in IDEAYA Biosciences during the 2nd quarter valued at $319,728,000. Janus Henderson Group PLC increased its holdings in shares of IDEAYA Biosciences by 1.1% in the 1st quarter. Janus Henderson Group PLC now owns 7,265,253 shares of the company’s stock worth $242,023,000 after purchasing an additional 78,797 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of IDEAYA Biosciences by 42.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,333,478 shares of the company’s stock worth $44,418,000 after purchasing an additional 394,621 shares in the last quarter. Finally, Bank of America Corp DE bought a new stake in shares of IDEAYA Biosciences in the 2nd quarter worth $38,244,000. Institutional investors own 98.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a report on Tuesday, September 22nd. Citizens Jmp reiterated a “market outperform” rating and issued a $42.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, September 1st. Wall Street Zen lowered IDEAYA Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Wedbush boosted their target price on IDEAYA Biosciences from $60.00 to $63.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Mizuho set a $44.00 target price on shares of IDEAYA Biosciences in a research note on Thursday, October 29th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $50.00.

IDEAYA Biosciences Trading Up 1.9%

Shares of IDYA opened at $31.24 on Friday. The firm has a market cap of $3.02 billion, a PE ratio of -6.96 and a beta of 0.08. The firm has a fifty day simple moving average of $36.28 and a two-hundred day simple moving average of $33.98. IDEAYA Biosciences, Inc. has a 1-year low of $26.81 and a 1-year high of $42.68.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.18) by ($0.04). The firm had revenue of $10.24 million for the quarter, compared to the consensus estimate of $7.58 million. IDEAYA Biosciences had a negative net margin of 1,157.18% and a negative return on equity of 39.78%. IDEAYA Biosciences’s quarterly revenue was up 14.6% compared to the same quarter last year. During the same period in the previous year, the company earned $1.33 earnings per share. As a group, research analysts forecast that IDEAYA Biosciences, Inc. will post -4.62 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Yujiro Hata sold 26,338 shares of the company’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $37.41, for a total transaction of $985,304.58. Following the completion of the sale, the chief executive officer owned 690,695 shares in the company, valued at approximately $25,838,899.95. This represents a 3.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.70% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc (NASDAQ:IDYA) is a biotechnology company focused on discovering and developing precision medicines for cancer. Its research emphasizes synthetic lethality, biomarker-driven drug discovery and molecularly defined patient populations, with the goal of matching targeted therapies to specific genetic alterations in tumors.

The company’s pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily for genetically defined cancers, including metastatic uveal melanoma.